Abstract 14741: Asian Dust Has an Impact on the Incidence of Acute Myocardial Infarction ~a Time-stratified Case-crossover Study
Introduction: Air pollution, a mixture of gases and particles that come from manmade and natural sources, has been shown to increase hospi¬tal admission and mortality attributable to cardiovascular diseases. Asian dust (AD), a windblown sand dust originating from mineral soil in the desert, and PM2.5, which comes from cars and trucks, power plants, industrial boilers, other industrial sources and wildfires, are the standard for particulate matter representing air pollution.
Hypothesis: We assessed the hypothesis that AD and PM2.5 were associated with the incidence of acute myocardial infarction (AMI) in Kumamoto prefecture.
Methods: Kumamoto prefecture is located in southwestern Japan and has a stable population of 1.8 million. A total of 3,670 AMI patients in 2009-2012 in Kumamoto prefecture were entirely registered and 199 AMI patients whose onset date was not definite were excluded in the present study. A time-stratified case-crossover study was conducted to assess the association between particulate matters and AMI incidence. Within-subject comparisons were made between a case and control periods in this design. The study estimated the odds ratios and 95% confidence intervals associated with AMI incidence during the case day to a few previous days using conditional logistic regression.
Results: The case-crossover analysis showed that PM2.5 was not significantly associated with the incidence of AMI (Figure upper). However, the results after adjustment for temperature and relative humidity revealed a close association between AD and the incidence of AMI (Figure lower). The strong association was observed on day 1. Adding co-pollutants including oxidants, nitrogen dioxide and sulfur dioxide in the basic model did not substantially alter the results.
Conclusions: AD increases the incidence of AMI compared with PM2.5. Attention should be called to patients already at high risk for cardiovascular disease in case of an official announcement of AD warning.
Author Disclosures: S. Kojima: None. K. Matsui: None. K. Ueda: None. H. Nitta: None. H. Ogawa: Other Research Support; Modest; AstraZeneca, Astellas, Boehringer lngelheim, Bristol-Myers Squibb, Daiichi Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Novartis, Pfizer, Sanofi, Takeda. Other Research Support; Significant; Bayer, Chugai, Otsuka. Honoraria; Modest; AstraZeneca, Bayer, Pfizer, Sanofi, Takeda. Honoraria; Significant; Daiichi Sankyo, MSD.
- © 2014 by American Heart Association, Inc.